Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Glenmede Trust Co. NA

Glenmede Trust Co. NA raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 11.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 119,811 shares of the medical instruments supplier’s stock after acquiring an additional 12,048 shares during the quarter. Glenmede Trust Co. NA’s holdings in Becton, Dickinson and Company were worth $28,886,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. Massachusetts Financial Services Co. MA lifted its stake in shares of Becton, Dickinson and Company by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after purchasing an additional 460,440 shares during the period. Ameriprise Financial Inc. increased its holdings in Becton, Dickinson and Company by 6.4% in the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after buying an additional 302,893 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after acquiring an additional 346,720 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after acquiring an additional 1,317,723 shares during the period. Finally, Clearbridge Investments LLC grew its holdings in shares of Becton, Dickinson and Company by 3.1% in the 2nd quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock worth $697,513,000 after acquiring an additional 89,157 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on BDX. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Raymond James cut their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Trading Down 1.0 %

Shares of Becton, Dickinson and Company stock opened at $221.96 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The business’s fifty day moving average is $234.64 and its two-hundred day moving average is $234.32. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The firm has a market cap of $64.16 billion, a PE ratio of 37.37, a P/E/G ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business posted $3.42 earnings per share. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date of this dividend is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 63.97%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.